Aim: To investigate sodium-glucose cotransporter 2 inhibitor (SGLT2i)-induced changes in ketogenic enzymes and transporters in normal and diabetic mice models. Results: In both normal and diabetic mice, SGLT2i increased beta-hydroxybutyrate (BHB) content in liver, kidney and colon tissue, as well as in serum and urine. In these organs, SGLT2i upregulated mRNA expression of ketogenic enzymes, 3-hydroxy-3-methylglutaryl-coenzyme A synthase 2 and 3-hydroxy-3-methylglutaryl-coenzyme A lyase. Similar patterns were observed in the kidney, ileum and colon for mRNA and protein expression of sodium-dependent monocarboxylate transporters (SMCTs), which mediate the cellular uptake of BHB and butyrate, an important substrate for intestinal ketogenesis. In diabetic mice under euglycaemic conditions, SGLT2i increased major ketogenic enzymes and SMCTs, while insulin suppressed ketogenesis.
reabsorption and increasing glucosuria to reduce blood glucose levels. 1, 2 SGLT2i action is independent of insulin, and hypoglycaemia is less frequently reported compared with many other classes of antihyperglycaemic agents. 3 Beyond glucose control, SGLT2i confer additional favourable effects on conventional cardiovascular risk factors, such as lowering blood pressure and body weight. 4, 5 Two recent major clinical trials employing SGLT2i reported an impressive beneficial effect of SGLT2i on cardiorenal outcomes. [6] [7] [8] [9] Another noteworthy characteristic of SGLT2i is that they are associated with elevated plasma ketone levels in humans. [10] [11] [12] SGLT2i enhance glucosuria by effectively lowering plasma glucose levels, resulting in decreased fasting insulin and increased fasting glucagon. [13] [14] [15] These hormonal changes cause upregulation of lipolysis in adipose tissue, 12, 16 and also promote a shift in whole-body substrate utilization from carbohydrate to fat, which mechanistically explains the elevation of ketone bodies in patients treated with
SGLT2i. 14 However, the role of SGLT2i in ketone body metabolism in tissues other than liver is largely unknown.
Ketone bodies are a vital alternative source of energy during starvation periods. 17, 18 Ketone bodies, β-hydroxybutyrate (BHB), acetoacetate (AcAc) and acetone are accumulated during starvation. AcAc can be spontaneously converted into acetone, which has no metabolic effect, or into BHB, which is the most stable form of ketone body. 19 During a period of starvation, upregulated fatty acid β-oxidation leads to an increased NADH/NAD+ ratio, which promotes conversion of AcAc into BHB. 20, 21 In states of hyperketonemia and ketonuria, BHB concentrations are several times higher than those of AcAc or acetone in both blood and urine. 17 Levels of circulating ketone bodies are regulated by the balance between ketogenesis and ketolysis. 22 Free fatty acids (FFAs) are the major source of ketone bodies, and their availability primarily determines the rate of ketogenesis. 17 In mammals, the primary ketogenic organ is the liver, although the kidney and intestine have potential capacity for extrahepatic ketogenesis. 18, [23] [24] [25] FFAs are taken up into hepatocytes, and ß-oxidation transforms FFAs into acetyl-CoA and acetoacetyol-CoA (AcAc-CoA). Then, 3-hydroxy-3-methtylglutaryl-CoA (HMG-CoA) is formed by acetyl-CoA and AcAc-CoA, followed by subsequent change to AcAc, and a more stable form of BHB. 12 The rate-limiting mitochondrial enzyme for ketogenesis is 3-hydroxy-3-methylglutaryl-coenzyme A synthase 2 (HMGCS2), which plays a role in condensation of acetyl-CoA and reduces AcAc to BHB, modulating its mitochondrial redox potential. 27, 28 The kidney also contributes to ketone body homeostasis via ketone-reabsorptive capacity using proximal tubular transporters, sodium-dependent monocarboxylate transporter (SMCT) 1 and 2. 12, 18, 29, 30 Especially in the small intestine and colon, SMCT1 mediates uptake of butyrate in addition to that of BHB, 30, 31 and butyrate can be a source of ketone body formation. 32 Ketone has broadly favourable effects, including as a fuel source to produce adenosine triphosphate (ATP) more efficiently than glucose or FFAs in a failing heart. 33, 34 Recent studies also reported that a ketogenic diet extended longevity and health span in animal models, 35 and ketone bodies have an anti-inflammatory property that operates by inhibiting the Nod-like receptor pyrin domain containing protein 3 (NLRP3) inflammasome. [36] [37] [38] Therefore, SGLT2i-induced elevated ketone levels might have a beneficial effect in patients with diabetes, as diabetes is a combined condition of chronic inflammation and restricted glucose usage. 34, 39, 40 Very little is known about how SGLT2i increase serum ketone levels in terms of specific responses in ketogenic organs. We designed our study to determine whether SGLT2i contribute to ketogenic metabolism by modulating major enzymes (HMGCS2, HMGCL and BDH1) and transporters (SMCT 1 and 2) in various organs using normal and diabetic mouse models.
| MATERIALS AND METHODS

| Animal experiments
Six-to 10-week-old male C57BL/6J mice as normal model and After normal and diabetic mice were sacrificed, blood was collected via heart puncture and tissues were harvested. Specimens were snap-frozen in liquid nitrogen and maintained at −80 C until analysed.
All animal studies were approved by the Animal Care and Use Committee of the Yonsei University College of Medicine. Increased HMGCS2 with SGLT2i administration was more prominent in the ileum in the 16 hours fasting condition (P < 0.001; Figure 2D ).
| Cell culture and treatment
SMCT1 mRNA expression was also upregulated in association with longer fasting duration and SGLT2i treatment in the kidney, ileum and colon ( Figure 2F -H). The SMCT2 protein level in the kidney showed a similar pattern by western blot analysis ( Figure 2K ). Additionally, we measured mRNA levels of peroxisome proliferator-activated receptor-α (PPARα), a master transcription factor responsible for regulating the majority of genes necessary for ketone body synthesis. [41] [42] [43] PPARα expression was increased in the liver and colon in association with prolonged fasting and SGLT2i administration ( Figure 2I ,J).
3.3 | In diabetic mice, SGLT2i increases serum, urine and tissue BHB levels with upregulated ketogenic enzymes and transporters
The ketogenic effect of SGLT2i administration in db/db mice was in the ileum and colon of db/db mice, whereas no difference was observed in the liver and kidney (Supporting Information Figure S2B -E).
Another ketogenic enzyme, BDH1 mRNA levels also tended to be lower in insulin-treated mice compared with SGLT2i-treated mice, but a statistical difference was observed only in the kidney and ileum (Supporting Information Figure S2F -I).
Regarding SMCT1 mRNA expression, there was no apparent difference in the kidney with SGLT2i compared with insulin treatment ( Figure 3L ). However, in the colon of db/db mice, SMCT1 was downregulated by insulin, while its level was preserved by SGLT2i
( Figure 3M ). Furthermore, SGLT2i elevated protein expression of SMCT2 in the kidney of db/db mice, indicating a potential increase in BHB uptake ( Figure 3N ).
Taken together, these results suggest that an increased insulin level suppressed ketogenesis, ameliorating hyperglycaemia in a diabetic mice model. On the contrary, SGLT2i preserved ketogenesis in diabetic mice, although SGLT2i also lowered serum glucose levels.
3.4 | SGLT2i upregulates SMCT 1 and 2 expression by various mechanisms in renal proximal tubular and intestinal epithelial cells SMCT1 and 2 mediate renal and intestinal absorption of multiple substances, including BHB and butyrate, an important substrate for intestinal ketogenesis. 32 We elucidated the underlying mechanism by which SGLT2i upregulates ketogenic enzymes and transporters in the kidney and intestine using in vitro experiments. Both low glucose and high BHB conditions, which represent SGLT2i-induced metabolic changes, significantly increased SMCT1 and 2 in human kidney 
| DISCUSSION
Our objective was to determine how ketogenic organs respond to SGLT2i administration to regulate specific enzymes and transporters.
Upregulated ketogenesis by SGLT2i administration was physiologically interrelated among various organs ( Figure 5 ). We showed that SGLT2i produced elevated BHB levels in liver, kidney and colon tissue, and in serum and urine, in normal mice. SGLT2i administration upregulated ketogenic enzymes (HMGCS2, HMGCL and BDH1) and SMCTs in ketogenic organs. In diabetic mice, tissue BHB levels were also increased with SGLT2i administration, while serum insulin levels were decreased compared with vehicle and insulin treatment. Ketogenic enzymes and transporters were decreased in insulin-treated mice, but were maintained or increased by SGLT2i treatment. In normal mice, serum BHB levels were comparable between 8 hours fasting with SGLT2i and 16 hours fasting alone, indicating that SGLT2i mimics more prolonged fasting. Notably, in the kidney and colon, tissue BHB levels after 8 hours fasting with SGLT2i were even higher than after 16 hours fasting alone, suggesting the metabolic shift to ketogenesis differs among tissue types. HMGCS2 mRNA expression was 1.2-fold increased by SGLT2 administration in 8 hours fasting in liver, and 1.6-and 2.5-fold increases were observed in kidney and colon, respectively. These results suggest that SGLT2i induces a shift toward elevated systemic BHB levels greater than would be expected based on actual fasting duration.
Previous studies reported that serum BHB levels were approximately 2-and 5-fold higher, respectively, after 8 and 16 hours of fasting compared with non-fasting levels. 46 To date, BHB levels in ketogenic organ tissue have been rarely measured according to fasting duration or SGLT2i administration. Liver BHB was measured as 0.15 nmol/mg in a non-fasting condition and rose to 2.0 nmol/mg in a 24 hours fasting state in normal rats (100-150 g). 47 In our study, the BHB level in liver tissue in a 16 hours fasting condition was 1.85 nmol/mg, increasing to 2.70 nmol/mg by adding SGLT2i.
HMGCS2 is considered a key enzyme whose upregulation is essential to ketogenesis. 26, 46, 48, 49 A previous animal study using C57BL/6J mice reported that hepatic HMGCS2 mRNA levels in 8 and 16 hours fasting conditions were 3-and 6-fold higher, respectively, compared with those in a fed state. 46 Similarly, our data showed 2-and 5-fold increases, respectively, in HMGCS2 expression in 8 and 16 hours fasting states compared with mice in a fed state. BDH1 was characterized as a marker of liver ketogenesis in previous studies. 18, 49 However, BDH1 can be a marker of both BHB production and utilization, as extrahepatic BDH1 can catalyse the conversion of BHB back into AcAc. 18, 50, 51 Although its exact role in other ketogenic organs needs further elucidation, we showed that BDH1 was upregulated by fasting and SGLT2i treatment in accordance with increased BHB in liver, kidney and intestine tissues.
Absorption of ketone bodies through the kidney and intestine also contributes to ketone homeostasis. 18, [52] [53] [54] [55] In a previous report of 12 obese subjects undergoing total starvation up to 24 days, reabsorption rates of AcAc and BHB significantly increased with a constant renal clearance rate. 52 In a study using rats, oral ketone supplementation caused a rapid and sustained elevation of serum BHB, indicating intestinal capacity for ketone absorption. 55 Our data revealed that gradual increases in renal and intestinal tissue BHB levels by fasting and SGLT2i co-occurred with increased SMCT 1 and in vitro experiments. 58, 59 In this study, we observed that SMCT 1 and 2 expression increased in a low glucose condition or after inhibition of cellular glucose uptake by SGLT2i, pointing to an association with attenuated intracellular ER stress. 44, 45 Furthermore, the ER stress inhibitor PBA upregulated SMCT expression in renal proximal tubular cells, supporting the hypothesis of ER as a possible determinant of renal expression.
We showed that hormonal and metabolic changes enhance ketogenesis by modulating ketogenic enzymes. In our study, serum insulin level was significantly reduced by SGLT2i administration and longer fasting duration in normal mice; in diabetic mice, SGLT2i decreased serum insulin levels <0.5 ng/mL. In both mouse models, SGLT2i administration significantly reduced fasting serum levels of insulin, a potent inhibitor of PPARα, which is responsible for activation of key ketogenic genes, including HMGCS2. 43, 49, 60 Increased expression of PPARα in the liver and colon by fasting and SGLT2i treatment conditions supports PPARα's role in upregulation of ketogenesis by SGLT2i. In addition to SGLT2i's ability to modulate insulin, it can also trigger glucagon secretion in pancreatic α cells. 61 As glucagon is a catabolic hormone that induces β-oxidation and subsequent ketogenesis, 43 SGLT2i-induced increased circulating glucagon may contribute to ketogenesis; this linkage should be investigated in further studies. We also suggest that the positive feedback mechanism marginally contributes to increased ketogenesis by SGLT2i, because the presence of high BHB levels also induces upregulation of HMGCS2 in intestinal cells.
Patients with diabetes have different ketone body homeostasis compared with non-diabetics. 62 In the former, baseline serum BHB levels were elevated compared with the latter, 11, 63 who also have a higher rate of ketone utilization and production. 62 Conditions such as type 2 diabetes, characterized by a deprivation of glucose utilization, lower insulin-to-glucagon ratio, and increased circulating FFAs by accelerated lipolysis, can enhance ketogenesis. 64 Similarly, serum BHB levels in a 16 hours fasting state in db/db mice were higher than in normal mice. In diabetic mice treated with either insulin or SGLT2i, SGLT2i maintained or increased circulating and tissue BHB levels along with ketogenic enzymes and SMCTs, while insulin treatment suppressed these.
This study has several weaknesses, which can be addressed by further investigation. First, a major limitation when measuring metabolite concentration is the lack of dynamic information in the context of metabolic fluxes. 65, 66 Based on the present data, we could not conclude to what extent absorption and synthesis of BHB contribute to increment in ketone levels. Because the application of stable isotope labelling can provide information about metabolic flux including ketone body turnover, 48, 66, 67 confirmatory experiments regarding enhanced ketogenesis in each organ should be conducted. Second, although recent studies reported favourable effects of ketone bodies in healthy subjects, it remains unknown whether increasing ketone levels would have a beneficial metabolic effect in a diabetic condition.
Third, the effects of SGLT2i-induced changes on various ketogenic substrates were not fully examined. In addition to butyrate, ketone bodies are mainly derived from fatty acid and amino acids, such as leucine, which also contribute to ketone body generation. 18, 68 In conclusion, we demonstrated that SGLT2i increased circulating and tissue BHB levels with upregulating ketogenic enzymes (HMGCS2, HMGCL and BDH1) and ketone body transporters (SMCT 1 and 2) in the liver, kidney and intestine, in both normal and diabetic conditions. Considering the potential metabolic benefit of increased BHB levels mimicking prolonged fasting, future studies are needed to more deeply investigate the mechanism and physiology underlying the effects of SGLT2i in humans. FIGURE 5 Integrated physiologic response to SGLT2i via inter-organ crosstalk. SGLT2i increases BHB content in liver, kidney and colon tissue, as well as in serum and urine. In ketogenic organs, SGLT2i upregulates mRNA expression of the ketogenic enzymes, HMGCS2, HMGCL and BDH1. In the kidney, ileum and colon, SGLT2i also increases mRNA and protein expression of SMCT, which mediates the cellular uptake of BHB and butyrate, an important substrate for intestinal ketogenesis. Decreased insulin and increased glucagon levels, as a result of SGLT2i administration, promote lipolysis with release of FFAs, and activates PPARα, all of which enhances ketogenesis. Attenuated ER stress by lowering glucose is a possible contributor to increased renal expression of SMCT according to SGLT2i administration
